Reviewing P3 Health Partners (NASDAQ:PIII) and Better Therapeutics (NASDAQ:BTTX)

P3 Health Partners (NASDAQ:PIIIGet Rating) and Better Therapeutics (NASDAQ:BTTXGet Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings and profitability.

Risk and Volatility

P3 Health Partners has a beta of 1.97, suggesting that its stock price is 97% more volatile than the S&P 500. Comparatively, Better Therapeutics has a beta of 2.23, suggesting that its stock price is 123% more volatile than the S&P 500.

Profitability

This table compares P3 Health Partners and Better Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
P3 Health Partners N/A N/A N/A
Better Therapeutics N/A -168.11% -72.46%

Earnings and Valuation

This table compares P3 Health Partners and Better Therapeutics’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
P3 Health Partners N/A N/A N/A N/A N/A
Better Therapeutics $10,000.00 4,701.11 -$40.33 million N/A N/A

P3 Health Partners has higher earnings, but lower revenue than Better Therapeutics.

Insider and Institutional Ownership

7.5% of Better Therapeutics shares are owned by institutional investors. 59.4% of Better Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and target prices for P3 Health Partners and Better Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
P3 Health Partners 0 0 1 0 3.00
Better Therapeutics 0 0 2 0 3.00

Better Therapeutics has a consensus target price of $15.00, suggesting a potential upside of 657.58%. Given Better Therapeutics’ higher possible upside, analysts clearly believe Better Therapeutics is more favorable than P3 Health Partners.

Summary

Better Therapeutics beats P3 Health Partners on 6 of the 8 factors compared between the two stocks.

About P3 Health Partners

(Get Rating)

P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. The company is based in Henderson, Nevada.

About Better Therapeutics

(Get Rating)

Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.

Receive News & Ratings for P3 Health Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for P3 Health Partners and related companies with MarketBeat.com's FREE daily email newsletter.